investorscraft@gmail.com

Intrinsic Value of Aridis Pharmaceuticals (ARDS)

Previous Close$0.00
Intrinsic Value
Upside potential
Previous Close
$0.00
* Our model cannot be used “out of the box” for the valuation of this stock. You can still do your own valuation by changing the valuation input parameters.

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-09-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %101.4NaN
Revenue, $3NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m33NaN
Operating income, $m-30NaN
EBITDA, $m-30NaN
Interest expense (income), $mNaN
Earnings before tax, $m-29NaN
Tax expense, $m1NaN
Net income, $m-30NaN

BALANCE SHEET

Cash and short-term investments, $m5NaN
Total assets, $m15NaN
Adjusted assets (=assets-cash), $m10NaN
Average production assets, $m1NaN
Working capital, $m-25NaN
Total debt, $m6NaN
Total liabilities, $m39NaN
Total equity, $m-24NaN
Debt-to-equity ratio-0.253NaN
Adjusted equity ratio-2.538NaN

CASH FLOW

Net income, $m-30NaN
Depreciation, amort., depletion, $m0NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-29NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-29NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m-25
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount